Skip to main content

Table 2 Patients’ outcomes by study phase

From: A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: A stepped-wedge cluster randomised implementation trial

Characteristic Referred1 Discussed2 Consultation3
n/N (%) Adjusted # RR (95% CI) n/N (%) Adjusted # RR (95% CI) n/N (%) Adjusted # RR (95% CI)
All patients: 325/1071 (30%)   354/1071 (33%)   278/1071 (26%)  
Study phase
 Control 154/505 (30%) ref. 88/505 (17%) ref. 138/505 (27%) ref.
 Transition 41/159 (26%) 0.99 (0.68, 1.46) 26/159 (16%) 1.52 (0.90, 2.58) 33/159 (21%) 0.99 (0.72, 1.35)
 Intervention 130/407 (32%) 1.06 (0.74, 1.51) 240/407 (59%) 4.32 (2.40, 7.75) 107/407 (26%) 1.05 (0.74, 1.51)
p value   0.879   < 0.001   0.896
  1. 1Patient referred within 4 months after prostatectomy to either a radiation oncologist or to the RAVES trial
  2. 2Patient discussed at MDT meeting within 4 months after prostatectomy
  3. 3Patient had consultation with radiation oncologist within 6 months after RP following referral within 4 months after RP
  4. #Adjusted for age at prostatectomy (40–59, 60–69, 70+), extracapsular extension (no, yes, unsure), positive surgical margin (no, yes, unsure), seminal vesicle invasion (no, yes, unsure), regional lymph node involvement (no, yes, unsure), post-operative Gleason score (6–7, 8, 9–10, unsure), maximum PSA level within 4 months after RP (< 0.1 ng/ml, ≥ 0.1 ng/ml, no PSA test recorded), number of co-morbidities (0, 1, 2, 3+), site (1 through 9), calendar time period of surgery (four time periods) and urologist as the GEE clustering variable
  5. 19 patients with “unsure” extracapsular extension, positive surgical margin and/or seminal vesicle invasion were excluded from regression analysis because low numbers in those groups prevented model convergence